- Xtant Medical Holdings (XTNT, Financial) launches Trivium™, a next-gen bone graft with PureLoc™ Fiber Technology.
- Trivium™ enhances surgical precision and tissue integration, using the proven BacteRinse® processing method.
- Available nationwide, Trivium™ expands Xtant Medical's regenerative medicine portfolio.
Xtant Medical Holdings, Inc. (XTNT), a global leader in medical technology, has announced the release of Trivium™, a revolutionary demineralized bone matrix (DBM) allograft. This advanced product is engineered with PureLoc™ Fiber Technology, combining three synergistic elements that enhance structure, handling, and biological activity. This innovative design aims to elevate standards in bone grafting procedures.
The unique architecture of Trivium™ features intertwined structures and interconnected porosity, which are designed to support cell attachment and tissue ingrowth, crucial for successful bone integration. Its superior moldability enables precise placement across various surgical applications, making it a dependable choice for surgeons.
Trivium™ is manufactured using Xtant Medical's proprietary BacteRinse® processing method. This method has been clinically validated for over twenty years to preserve bone morphogenetic proteins (BMPs), ensuring the graft maintains the critical bioavailable growth factors necessary for initiating and supporting bone repair.
"Trivium represents a significant advancement in bone grafting technology," said Sean Browne, President and CEO of Xtant Medical. "With its enhanced composition and high BMP retention, Trivium provides surgeons with a versatile solution for a multitude of surgical scenarios, delivering consistent and reliable outcomes for patients."
This launch highlights Xtant Medical's commitment to innovation in the field of regenerative medicine, offering a high-performance graft that ensures optimal surgical outcomes. Trivium is now available through the company's extensive network of independent agents nationwide, signaling a full commercial rollout.
